Additionally, survival of EML4-ALK fusion NSCLC was inhibited by anti-PD-1 or ALK inhibitor alone, but synergistic tumor killing effect of ALK inhibitor PD-1 inhibitor was not shown. This evidence concerns the gene ALK and neoplasm.